Vanguard Global Advisers
ALDX icon

Vanguard Global Advisers’s Aldeyra Therapeutics ALDX Stock Holding History

Vanguard Global Advisers’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$21.8K Hold
17,687
– – ﹤0.01% 3333
2026
Q2 		$37.7K Hold
17,687
– – ﹤0.01% 3160
2026
Q1 		$29.9K Buy
+17,687
New +$77.5K ﹤0.01% 3196

Other funds holding ALDX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Vanguard Global Advisers's ALDX Position: Q3 2026 in Review

Vanguard Global Advisers held its Aldeyra Therapeutics (ALDX) position steady in Q3 2026 at 17,687 shares worth $21.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3333.

Vanguard Global Advisers first reported a position in ALDX in Q1 2026 and has held it in 3 quarters since. The position peaked at $37.7K in Q2 2026. 63 funds tracked by Wall St. Rank hold ALDX as of Q3 2026.

  • Vanguard Global Advisers held 17,687 shares of Aldeyra Therapeutics worth $21.8K as of Q3 2026.
  • Vanguard Global Advisers left its Aldeyra Therapeutics share count unchanged in Q3 2026.
  • Aldeyra Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3333 holding.
  • Vanguard Global Advisers first reported a position in Aldeyra Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Aldeyra Therapeutics position peaked at $37.7K in Q2 2026.
  • 63 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.